| EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations MT McCabe, HM Ott, G Ganji, S Korenchuk, C Thompson, GS Van Aller, ... Nature 492 (7427), 108-112, 2012 | 1889 | 2012 |
| EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation W Béguelin, R Popovic, M Teater, Y Jiang, KL Bunting, M Rosen, H Shen, ... Cancer cell 23 (5), 677-692, 2013 | 904 | 2013 |
| A DNA hypomethylation signature predicts antitumor activity of LSD1 inhibitors in SCLC HP Mohammad, KN Smitheman, CD Kamat, D Soong, KE Federowicz, ... Cancer cell 28 (1), 57-69, 2015 | 487 | 2015 |
| Identification of potent, selective, cell-active inhibitors of the histone lysine methyltransferase EZH2 SK Verma, X Tian, LV LaFrance, C Duquenne, DP Suarez, KA Newlander, ... ACS medicinal chemistry letters 3 (12), 1091-1096, 2012 | 404 | 2012 |
| Discovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of rapamycin SD Knight, ND Adams, JL Burgess, AM Chaudhari, MG Darcy, ... ACS Medicinal Chemistry Letters 1 (1), 39-43, 2010 | 404 | 2010 |
| SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer PK Mazur, N Reynoird, P Khatri, PWTC Jansen, AW Wilkinson, S Liu, ... Nature 510 (7504), 283-287, 2014 | 395 | 2014 |
| Smyd3 regulates cancer cell phenotypes and catalyzes histone H4 lysine 5 methylation GS Van Aller, N Reynoird, O Barbash, M Huddleston, S Liu, AF Zmoos, ... Epigenetics 7 (4), 340-343, 2012 | 207 | 2012 |
| Epigallocatechin gallate (EGCG), a major component of green tea, is a dual phosphoinositide-3-kinase/mTOR inhibitor GS Van Aller, JD Carson, W Tang, H Peng, L Zhao, RA Copeland, ... Biochemical and biophysical research communications 406 (2), 194-199, 2011 | 186 | 2011 |
| Effects of oncogenic p110α subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase JD Carson, G Van Aller, R Lehr, RH Sinnamon, RB Kirkpatrick, KR Auger, ... Biochemical Journal 409 (2), 519-524, 2008 | 156 | 2008 |
| Identification, Substrate Specificity, and Inhibition of theStreptococcus pneumoniae β-Ketoacyl-Acyl Carrier Protein Synthase III (FabH) SS Khandekar, DR Gentry, GS Van Aller, P Warren, H Xiang, C Silverman, ... Journal of Biological Chemistry 276 (32), 30024-30030, 2001 | 137 | 2001 |
| Biochemical and genetic characterization of the action of triclosan on Staphylococcus aureus C Slater-Radosti, G Van Aller, R Greenwood, R Nicholas, PM Keller, ... Journal of Antimicrobial Chemotherapy 48 (1), 1-6, 2001 | 119 | 2001 |
| First X-ray cocrystal structure of a bacterial FabH condensing enzyme and a small molecule inhibitor achieved using rational design and homology modeling RA Daines, I Pendrak, K Sham, GS Van Aller, AK Konstantinidis, ... Journal of medicinal chemistry 46 (1), 5-8, 2003 | 110 | 2003 |
| Long residence time inhibition of EZH2 in activated polycomb repressive complex 2 GS Van Aller, MB Pappalardi, HM Ott, E Diaz, M Brandt, BJ Schwartz, ... ACS chemical biology 9 (3), 622-629, 2014 | 61 | 2014 |
| Development and validation of reagents and assays for EZH2 peptide and nucleosome high-throughput screens E Diaz, CA Machutta, S Chen, Y Jiang, C Nixon, G Hofmann, D Key, ... Journal of biomolecular screening 17 (10), 1279-1292, 2012 | 58 | 2012 |
| Structure-based design of a novel SMYD3 inhibitor that bridges the SAM-and MEKK2-binding pockets GS Van Aller, AP Graves, PA Elkins, WG Bonnette, PJ McDevitt, ... Structure 24 (5), 774-781, 2016 | 54 | 2016 |
| Mechanism of time-dependent inhibition of polypeptide deformylase by actinonin GS Van Aller, R Nandigama, CM Petit, WE DeWolf, CJ Quinn, KM Aubart, ... Biochemistry 44 (1), 253-260, 2005 | 45 | 2005 |
| Reversal of nitroglycerin tolerance in vitro by the cGMP-phosphodiesterase inhibitor zaprinast ED Pagani, GS VanAller, B O'Connor, PJ Silver European journal of pharmacology 243 (2), 141-147, 1993 | 42 | 1993 |
| Inhibition of LSD1 as a therapeutic strategy for the treatment of acute myeloid leukemia RG Kruger, H Mohammad, K Smitheman, M Cusan, Y Liu, M Pappalardi, ... Blood, The Journal of the American Society of Hematology 122 (21), 3964-3964, 2013 | 35 | 2013 |
| Cyclic GMP potentiation by WIN 58237, a novel cyclic nucleotide phosphodiesterase inhibitor. PJ Silver, RL Dundore, DC Bode, L de Garavilla, RA Buchholz, ... Journal of Pharmacology and Experimental Therapeutics 271 (3), 1143-1149, 1994 | 34 | 1994 |
| Reversal or nitroglycerin tolerance by the cGMP phosphodiesterase inhibitor zaprinast PJ Silver, ED Pagani, L de Garavilla, GS VanAller, ML Volberg, PF Pratt European journal of pharmacology 199 (1), 141-142, 1991 | 30 | 1991 |
